Atara Biotherapeutics Inc

-0.28 (-1.62%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.44B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$5.18 Million
Adjusted EPS-$0.90
See more estimates
10-Day MA$16.39
50-Day MA$14.04
200-Day MA$15.90
See more pivots

Atara Biotherapeutics Inc Stock, NASDAQ:ATRA

611 Gateway Boulevard, Suite 900, South San Francisco, California 94080
United States of America
Phone: +1.650.278.8930
Number of Employees: 437


Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.